• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Neuropathology: official journal of the Japanese Society of Neuropathology >Neuropathologic assessment of participants in two multi-center longitudinal observational studies: The Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN)
【24h】

Neuropathologic assessment of participants in two multi-center longitudinal observational studies: The Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN)

机译：两项多中心纵向观察研究的参与者的神经病理学评估：阿尔茨海默氏病神经影像学计划（ADNI）和显性遗传的阿尔茨海默氏病网络（DIAN）

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

It has been hypothesized that the relatively rare autosomal dominant Alzheimer disease (ADAD) may be a useful model of the more frequent, sporadic, late-onset AD (LOAD). Individuals with ADAD have a predictable age at onset and the biomarker profile of ADAD participants in the preclinical stage may be used to predict disease progression and clinical onset. However, the extent to which the pathogenesis and neuropathology of ADAD overlaps with that of LOAD is equivocal. To address this uncertainty, two multicenter longitudinal observational studies, the Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN), leveraged the expertise and resources of the existing Knight Alzheimer Disease Research Center (ADRC) at Washington University School of Medicine, St. Louis, Missouri, USA, to establish a Neuropathology Core (NPC). The ADNI/DIAN-NPC is systematically examining the brains of all participants who come to autopsy at the 59 ADNI sites in the USA and Canada and the 14 DIAN sites in the USA (eight), Australia (three), UK (one) and Germany (two). By 2014, 41 ADNI and 24 DIAN autopsies (involving nine participants and 15 family members) had been performed. The autopsy rate in the ADNI cohort in the most recent year was 93% (total since NPC inception: 70%). In summary, the ADNI/DIAN NPC has implemented a standard protocol for all sites to solicit permission for brain autopsy and to send brain tissue to the NPC for a standardized, uniform and state-of-the-art neuropathologic assessment. The benefit to ADNI and DIAN of the implementation of the NPC is very clear. The NPC provides final gold standard neuropathological diagnoses and data against which the antecedent observations and measurements of ADNI and DIAN can be compared.
机译：假设相对罕见的常染色体显性遗传性阿尔茨海默病（ADAD）可能是更频繁，零星，迟发性AD（LOAD）的有用模型。患有ADAD的个体发病年龄可预测，临床前阶段ADAD参与者的生物标志物谱可用于预测疾病进展和临床发作。但是，ADAD的发病机制和神经病理学与LOAD重叠的程度是模棱两可的。为了解决这种不确定性，两项多中心纵向观察研究，即阿尔茨海默氏病神经影像学倡议（ADNI）和优势遗传的阿尔茨海默氏病网络（DIAN），利用了华盛顿大学医学院现有的奈特阿尔茨海默氏病研究中心（ADRC）的专业知识和资源。美国密苏里州圣路易斯市的Medicine公司建立了神经病理学核心（NPC）。 ADNI / DIAN-NPC正在系统地检查所有在美国和加拿大的59个ADNI站点以及在美国（八个），澳大利亚（三个），英国（一个）和德国（两个）。截至2014年，已完成41例ADNI和24例DIAN尸检（涉及9名参与者和15名家庭成员）。最近一年的ADNI队列的尸检率为93％（自NPC成立以来的总数为70％）。总之，ADNI / DIAN NPC已为所有站点实施了标准协议，以征求大脑尸检的许可并将脑组织发送到NPC，以进行标准化，统一和最新的神经病理学评估。实施NPC对ADNI和DIAN的好处非常明显。 NPC提供了最终的金标准神经病理学诊断和数据，可以将ADNI和DIAN的先前观察结果与测量结果进行比较。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号